Sponsors
The bill prioritizes patient safety by restricting DTC advertising for newly approved drugs during the first 3 years and giving regulators authority to act on post-market risks, but this protection comes at the cost of delayed public access to information, reduced targeted outreach to underserved populations, and economic and administrative impacts on drug sponsors.
Patients (especially those with chronic conditions) and health systems will face fewer premature direct-to-consumer (DTC) marketing exposures during the first 3 years after drug approval, reducing the risk that people start therapies before important safety signals are known.
Patients can gain earlier access to beneficial information in specific cases because HHS may permit advertising in year three when there is demonstrated public-health value, enabling timely communications when justified.
Hospitals, health systems, consumers, and industry will get clearer, updated guidance because the FDA is required to revise drug-advertising regulations within one year, which could improve clarity and enforcement.
Patients who rely on DTC information (including Medicare and Medicaid beneficiaries and those in underserved areas) may have reduced access to information about newly approved treatments for up to 3 years, increasing dependence on clinicians and potentially delaying treatment decisions.
Pharmaceutical companies and small drug developers will face reduced marketing opportunities and potential revenue losses for newly approved drugs, which could alter launch strategies and weaken incentives for R&D.
Limiting social-media and targeted advertising may reduce outreach to underserved or remote patients, widening information gaps and disadvantaging people who rely on digital channels to learn about new therapies.
Based on analysis of 2 sections of legislative text.
Bans most direct-to-consumer advertising of newly approved prescription drugs for the first three years after FDA approval, with a limited third-year waiver and safety-based exceptions.
Introduced February 7, 2025 by Rosa L. Delauro · Last progress February 7, 2025
Bars most direct-to-consumer advertising of newly approved prescription drugs for the first three years after FDA approval, including on social media, while creating a narrow waiver process to allow third-year advertising if the Health Secretary finds clear public-health value. The agency may also restrict advertising after the initial three-year period if new safety concerns arise, and must update FDA drug-advertising regulations within one year; the rule applies to drugs approved on or after the date one year before enactment.